Julio Rosenstock, MD, FACE, Principal Investigator at Velocity and the leader of the Diabetes and Obesity CARE Council, unveiled data suggesting a potential breakthrough for adults with prediabetes. When administered oral semaglutide, trial participants achieved normoglycemia at 68 weeks.
Dr. Rosenstock commented, “Those people who participated in the OASIS 1 trial with prediabetes who received oral semaglutide experienced more HbA1c normalization and none progressed to type 2 diabetes.” Furthermore, the same group of adults with prediabetes lost an impressive 14.4% of their body weight by week 68, compared to 2.5% weight loss in the placebo group.
